Regenxbio Inc expected to post a loss of $1.26 a share - Earnings Preview
07/05/2024 03:58
* Regenxbio Inc RGNX.OQ RGNX.O is expected to show a
rise in
quarterly revenue when it reports results on May 8 for the
period ending March 31 2024
* The Rockville Maryland-based company is expected to
report a
22.9% increase in revenue to $23.525 million from $19.14 million
a year ago, according to the mean estimate from 8 analysts,
based on LSEG data.
* LSEG's mean analyst estimate for Regenxbio Inc is for a
loss of
$1.26 per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 1.7%
in the last three months.
* Wall Street's median 12-month price target for Regenxbio
Inc is
$39.50, above its last closing price of $16.87.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -1.30 -1.27 -1.43 Missed -12.5
Sep. 30 2023 -1.56 -1.52 -1.41 Beat 7.1
Jun. 30 2023 -1.43 -1.38 -1.66 Missed -19.9
Mar. 31 2023 -1.60 -1.54 -1.53 Beat 0.4
Dec. -1.24 -1.23 -1.38 Missed -11.8
31 2022
Sep. 30 2022 -1.46 -1.46 -1.75 Missed -19.7
Jun. 30 2022 -1.54 -1.53 -1.58 Missed -3.5
Jan. 1 0001 -1.35 -1.32 -1.79 Missed -36
This summary was machine generated May 7 at 02:58 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)